Low α2β1 Integrin Function Enhances the Proliferation of Fibroblasts from Patients with Idiopathic Pulmonary Fibrosis by Activation of the β-Catenin Pathway  by Xia, Hong et al.
The American Journal of Pathology, Vol. 181, No. 1, July 2012
Copyright © 2012 American Society for Investigative Pathology.
Published by Elsevier Inc. All rights reserved.
http://dx.doi.org/10.1016/j.ajpath.2012.03.034Matrix Pathobiology
Low 21 Integrin Function Enhances the
Proliferation of Fibroblasts from Patients with
Idiopathic Pulmonary Fibrosis by Activation
of the -Catenin PathwayHong Xia,* Jeremy Seeman,* Jian Hong,†
Polla Hergert,* Vidya Bodem,* Jose Jessurun,‡
Karen Smith,* Richard Nho,* Judy Kahm,*
Philippe Gaillard,§ and Craig Henke*
From the Departments of Medicine* and Laboratory Medicine
and Pathology‡ and the Biostatistical Design and Analysis
Center-Clinical and Translational Science Institute,§ University of
Minnesota, Minneapolis, Minnesota; and the First Affiliated
Hospital,† Nanjing Medical University, Nanjing, China
Idiopathic pulmonary fibrosis (IPF) is a progressive
and incurable fibroproliferative disorder character-
ized by unrelenting proliferation of fibroblasts and
their deposition of collagen within alveoli, resulting
in permanently scarred, nonfunctional airspaces.
Normally, polymerized collagen suppresses fibroblast
proliferation and serves as a physiological restraint to
limit fibroproliferation after tissue injury. The IPF
fibroblast, however, is a pathologically altered cell
that has acquired the capacity to elude the prolifera-
tion-suppressive effects of polymerized collagen. The
mechanism for this phenomenon remains incom-
pletely understood. Here, we demonstrate that ex-
pression of 21 integrin, a major collagen receptor,
is pathologically low in IPF fibroblasts interacting
with polymerized collagen. Low integrin expression
in IPF fibroblasts is associated with a failure to induce
PP2Aphosphatase activity, resulting in abnormally high
levels of phosphorylated (inactive) GSK-3 and high
levels of active -catenin in the nucleus. Knockdown of
-catenin in IPF fibroblasts inhibits their ability to pro-
liferate on collagen. Interdiction of21 integrin in con-
trol fibroblasts reproduces the IPF phenotype and leads
to the inability of these cells to activate PP2A, resulting
in high levels of phosphorylated GSK-3 and active
-catenin and in enhanced proliferation on collagen.
Our findings indicate that the IPF fibroblast phenotype
is characterized by low 21 integrin expression, result-
ing in a failure of integrin to activate PP2A phosphatase,
222which permits inappropriate activation of the -catenin
pathway. (Am J Pathol 2012, 181:222–233; http://dx.doi.
org/10.1016/j.ajpath.2012.03.034)
Idiopathic pulmonary fibrosis (IPF) is a prevalent and
progressive fibroproliferative lung disease that is incur-
able. Histologically, the fibroblastic focus is the major
morphological lesion of IPF. It consists of fibroblasts in a
type I collagen-rich matrix.1 The disease is characterized
by unrelenting progression of fibrotic tissue formation,
with expansion of fibroblasts within alveolar walls and
deposition of type I collagen resulting in the obliteration of
airspaces and subsequent impairment of gas exchange
that in turn leads to progressive hypoxia.2–5
Fibrillar type I collagen, a potent suppressor of normal
fibroblast proliferation, functions as a physiological re-
straint to limit fibroproliferation after injury.6–8 The 1 in-
tegrin is a cell surface matrix receptor that is critically
positioned at the apex of signaling pathways that regu-
late proliferation.9–19 We have previously shown that
pathological integrin signaling underlies the aberrant pro-
liferative capacity of human IPF lung fibroblasts.20,21 We
have found that 1 integrin interaction with polymerized
collagen suppresses normal fibroblast proliferation by
inhibition of the PI3K/Akt/S6K1 signal pathway via main-
tenance of high PTEN phosphatase activity. IPF fibro-
blasts circumvent this restraint, displaying a pathological
pattern of 1 integrin signaling in response to polymerized
collagen that results in aberrant activation of the PI3K/Akt/
S6K1 pathway via inappropriately low PTEN activity. It has
remained unclear, however, whether integrin regulation of
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Akt/S6K1 pathway or whether additional pathways are in-
volved. Although 21 integrin is the major type I collagen
receptor, neither its function in IPF fibroblasts nor the pre-
cise role that 21 integrin plays in aberrant proliferation
signaling has been previously examined.
Previous studies have found that -catenin is activated
in IPF,22,23 but the mechanism by which -catenin is
elevated in IPF remains incompletely understood. We
have discovered that 21 integrin expression is greatly
diminished when IPF fibroblasts are cultured on polym-
erized type I collagen, compared with control fibroblasts.
In a seminal study, Heino and colleagues24 determined
that 21 integrin is required for activation of the serine/
threonine phosphatase PP2A during cell interaction with
type I collagen. Here, we demonstrate that low 21
integrin expression results in the failure of IPF fibroblasts
to appropriately induce PP2A phosphatase activity when
interacting with collagen. This is associated with high
levels of phosphorylated (inactive) GSK-3, a PP2A sub-
strate, and very high levels of active -catenin. We dem-
onstrate that knockdown of -catenin decreases the ability
of IPF fibroblasts to proliferate on polymerized collagen.
These findings stand in marked contrast to those for control
fibroblasts, which express higher levels of 21 integrin and
robustly induce PP2A activity, thereby activating GSK-3
and suppressing -catenin. We demonstrate that inhibition
of 21 function by blocking antibody or knockdown of 1
integrin expression in control fibroblasts results in the inabil-
ity of these cells to appropriately induce PP2A phosphatase
activity when these cells interact with polymerized collagen.
Interdiction of 21 integrin function in control fibroblasts
increases the level of phosphorylated (inactive) GSK-3,
increases the level of active -catenin, and enhances con-
trol fibroblast proliferation on polymerized collagen, repli-
cating IPF fibroblast behavior. Our present findings indicate
that the pathological IPF fibroblast phenotype is character-
ized by abnormally low 21 integrin expression and func-
tion, which is linked to the failure to appropriately induce
PP2A phosphatase activity, and thus permitting the aber-
rant activation of the -catenin proliferation signal pathway.
Materials and Methods
Primary IPF and Normal Fibroblast Lines
Eight primary fibroblast lines were established from IPF
patients. Cells were obtained from lungs removed at the
time of transplantation or death. The diagnosis of IPF was
supported by history, physical examination, pulmonary
function tests, and high-resolution chest computed tomog-
raphy findings typical of IPF. In all cases, the diagnosis of
IPF was confirmed by microscopic analysis of lung tissue,
which exhibited the characteristic morphological findings of
interstitial pneumonia. All patients fulfilled the criteria for the
diagnosis of IPF as established by the American Thoracic
Society and the European Respiratory Society.25 Seven pri-
mary control adult human lung fibroblast lines were used.
These lines included fibroblasts derived from anatomically
normal lung tissue not used at the time of lung transplanta-tion (n  4) and histologically normal lung tissue distant
from carcinoid tumor (n  2) or distant from radiation-in-
duced fibrotic lung tissue (n  1). Primary lung fibroblast
lines were generated by explant culture and cultured in
high-glucose Dulbecco’s modified Eagle’s medium
(DMEM) containing 10% fetal calf serum. Fibroblasts were
used between passages 3 to 5. Cells were characterized as
fibroblasts as described previously.26 Use of human tissues
was approved by the Institutional Review Board at the Uni-
versity of Minnesota.
Antibodies
Anti-2 integrin-blocking antibody (MCA743) was ob-
tained from AbD Serotec (Raleigh, NC), anti-1 integrin
antibody was obtained from BD Biosciences (San Diego,
CA), and anti-GSK-3 antibody was obtained from Cell
Signaling Technology (Danvers, MA). Anti-21 integrin-
blocking antibody (BHA2.1), anti-PP2Ac antibody, and
active anti--catenin antibody were obtained from Milli-
pore (Billerica, MA). Anti-1 integrin, activated antibody
(clone HUTS4) was obtained from Millipore.
Collagen Matrices
Three-dimensional polymerized collagen matrices (final
concentration, 2 mg/mL) were prepared by neutralizing
the collagen solution with 1/6 volume of 6 DMEM and
diluting to a final volume with 1 DMEM to which fetal calf
serum was added at a final concentration of 1% fetal calf
serum. Gels formed after incubation of this solution at
37°C for 1 to 2 hours as described previously.13–15,20
Lentiviral Vectors, 1 Integrin, PP2Ac, and
Control shRNA
1 Integrin, PP2Ac, -catenin, and control short hairpin RNA
(shRNA) were obtained from the University of Minnesota
RNAi Core Facility. The constructs were incorporated into
the pGIPZ plasmid vector. The cells were infected with
lentiviral vectors at a multiplicity of infection of 1:20. Alter-
natively, IPF and control fibroblasts were infected with a
lentiviral vector containing wild-type 1 integrin, mutant 1
integrin (V737N), or control (empty vector) constructs.
Western Blot
Serum-starved fibroblasts were plated on extracellular
matrix-coated plates and lysed at the indicated times
using cell lysis buffer containing 150 mmol/L NaCl, 1
mmol/L EGTA, 50 mmol/L Tris pH 7.4, 1% Triton X-100,
1% Nonidet P-40, and 1% sodium deoxycholate with
protease inhibitors (complete protease inhibitor mixture
tablets; Roche Applied Science, Indianapolis, IN). West-
ern blot analysis was performed on the resulting lysates.
Proliferation Assay
Fibroblasts were serum-starved for 2 days and then
plated on polymerized collagen (2 mg/mL) matrix in
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onto polymerized collagen matrix, the medium was re-
placed with DMEMwith 10% fetal calf serum. The cells were
incubated with 10 mol/L bromodeoxyuridine for 5 hours
before the cells were harvested at 24 hours. The cells were
then stained with anti-bromodeoxyuridine antibody to quan-
tify DNA synthesis and 7-amino actinomycin D as a mea-
sure of total DNA. DNA synthesis was quantified by assess-
ing the percentage of bromodeoxyuridine-positive cells by
fluorescence-activated cell sorting according to the manu-
facturer’s instructions (BD Biosciences).
PP2A in Vitro Phosphatase Activity Assay
PP2A activity was assessed by dephosphorylation of the
phosphopeptide K-R-pT-I-R-R. Briefly, PP2Ac was immu-
noprecipitated from cell lysates with 4 g of anti-PP2Ac
antibody (C subunit, clone 1D6; Millipore) incubated with
Protein A agarose slurry, then washed with Tris-buffered
saline. Immunoprecipitated PP2A was then incubated with
10L Ser/Thr assay buffer (50mmol/L Tris-HCl, pH 7.0, and
100 mol/L CaCl2) and 30 L of the phosphopeptide sub-
strate according to the manufacturer’s instructions (Milli-
pore-Chemicon, Temecula, CA). The enzyme reaction was
terminated by adding 100L of malachite green phosphate
detection solution. PP2A activity was measured using a
microtiter plate reader at 650 nm.
Immunofluorescent Confocal Microscopy
Immunostaining was performed on paraffin-embedded
IPF and control lung tissue using an Axiovert 200M
confocal microscope (Carl Zeiss MicroImaging, Göttin-
gen, Germany). Primary antibodies included a poly-
clonal antibody to 2 integrin (1:200 dilution; Millipore),
a monoclonal antibody to 1 integrin (1:100 dilution;
BD Biosciences), and monoclonal (Sigma-Aldrich, St.
Louis, MO) and polyclonal (Abcam, Cambridge, MA)
antibodies to -smooth muscle actin (both at 1:200
dilution).
Immunofluorescence
Immunofluorescence studies were performed on IPF and
control fibroblasts cultured on glass coverslips. The cells
were then fixed, permeabilized, and incubated (60 min-
utes, room temperature) with the appropriate primary an-
tibody (-catenin). The cells were then incubated (60
minutes, room temperature) with Cy2 or Cy3 conjugated
secondary antibodies, followed by incubation (10 min-
utes, room temperature) with DAPI. Primary antibody anti-
-catenin was obtained from Millipore.
Immunohistochemistry
Immunohistochemistry (IHC) was performed on paraffin-
embedded lung tissue specimens, 5 m thick, using a
polyclonal antibody to human 2 integrin (Millipore) and a
monoclonal antibody to human 1 integrin (Abcam). The
sections were deparaffinized, rehydrated through a se-ries of graded methanol, and heated (95°C, 30 minutes)
in citrate buffer (pH 6.0) for antigen retrieval. The sections
were quenched with 0.3% H2O2 in methanol to inhibit
endogenous peroxidases and blocked with 5% normal
human serum (30 minutes). Endogenous avidin and bio-
tin binding sites were blocked (15 minutes) sequentially
using an avidin/biotin-blocking kit (Vector Laboratories,
Burlingame, CA); incubated (16 hours, 4°C) with primary
antibodies, and then rinsed and incubated with goat anti-
rabbit secondary antibody (30 minutes, room tempera-
ture), followed by ready-to-use horseradish peroxidase-
streptavidin complex (Vector Laboratories). Controls
consisted of secondary antibody only. Specific antibody
binding was detected by 3,3=-diaminobenzidine (Vector
Laboratories); ready-to-use hematoxylin was used as a
counterstain.
Statistical Analysis
Comparisons of data among each experiment were per-
formed with the Satterthwaite t-test where applicable.
Nonparametric data were assessed using the Wilcoxon
rank-sum test. All experiments were replicated a mini-
mum of three times. Data are expressed as means  SD.
P  0.05 was considered significant.
Results
21 Integrin Expression Is Decreased in IPF
Fibroblasts in Vitro
Our prior work demonstrated that IPF fibroblasts have
escaped the proliferation-suppressive effects of polym-
erized type I collagen.20,21 The mechanism involved
pathological 1 integrin signaling, resulting in aberrant
activation of the PI3K/Akt/S6K1 proliferation signal path-
way. Because 21 integrin is the major integrin that
mediates interaction with type I collagen, we sought to
examine the precise role that 21 plays in aberrant pro-
liferation signaling and its function in IPF fibroblasts. We
first examined 1 integrin expression by Western blot
analysis in primary lung fibroblasts derived from IPF pa-
tients (n 7) and control patients (n 7) and cultured on
polymerized type I collagen matrix. On the basis of our
prior studies showing aberrant activation of proliferation
signaling downstream of integrin,20,21 we expected that
1 integrin expression would be high in IPF fibroblasts.
Instead, we found that 1 integrin protein expression was
decreased in primary IPF fibroblasts cultured on polym-
erized collagen, compared with control fibroblasts (Fig-
ure 1A). Similar to our results for 1 integrin, we found that
2 integrin expression also was lower in IPF fibroblasts,
compared with control (Figure 1B). We also examined the
1 integrin activation state of IPF and control fibroblasts
cultured on polymerized collagen as a function of time.
There was a reduction in the level of activated 1 integrin
in IPF fibroblasts, compared with control (see Supple-
mental Figure S1 at http://ajp.amjpathol.org). To correlate
integrin expression with proliferation, we examined the
proliferative capacity of IPF and control fibroblasts cul-
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studies, we found that the ability of IPF fibroblasts to
proliferate on polymerized collagen was significantly in-
creased, compared with control fibroblasts (Figure 1C).20
Thus, during IPF fibroblast interaction with fibrillar type I
collagen, the expression of 21 integrin is low and the
proliferative capacity is increased, compared with control
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Figure 1. 21 integrin expression is decreased in IPF fibroblasts in vitro. A:
Western blot analysis of 1 integrin expression in primary lung fibroblasts
from IPF patients (n  7) and control patients (n  7), cultured on polym-
erized type I collagen matrix. GAPDH was the loading control. Relative
protein expression was determined as the densitometric ratio of 1 integrin
to GAPDH. Shown is the composite ratio of integrin to GAPDH expression
comparing IPF with control. B: Western blot analysis of 2 integrin expres-
sion in IPF and control fibroblasts from IPF patients (n  5) and control
patients (n  5). Relative protein expression was determined as the densi-
tometric ratio of 2 integrin to GAPDH. Shown is the composite ratio of
integrin to GAPDH expression, comparing IPF with control. C: Primary lung
fibroblasts from IPF patients (n  4) and control patients (n  4) were
cultured on 2 mg/mL polymerized collagen matrix for 24 hours, after which
cell numbers were quantified. Data are representative of three independent
experiments. BrdU, bromodeoxyuridine.fibroblasts.21 Integrin Expression Is Decreased in IPF
Fibroblastic Foci in Vivo
To determine whether low 21 integrin levels in IPF fi-
broblasts in vitro correlated with 21 integrin expression
in vivo, we analyzed 21 integrin expression in fibro-
blasts within type I collagen-rich fibroblastic foci in hu-
man IPF lung tissue by immunofluorescence. Using anti-
bodies recognizing 2 and 1 integrin subunits, we found
that cells within IPF fibroblastic foci displayed diminished
immunoreactivity for 2 or 1 integrin, compared with
epithelial cells overlying the fibroblastic foci, which were
strongly immunoreactive for 2 and 1 integrin (Figure
2A). Cells within the fibrotic reticulum were strongly im-
munoreactive for  smooth muscle actin. As a semiquan-
titative gauge of integrin staining in IPF and control spec-
imens, we compared the intensity of 2 and 1
immunoreactivity in epithelial cells lining large airways,
using high-power merged immunofluorescent images
(Figure 2A; see also Supplemental Figure S2, A and B, at
http://ajp.amjpathol.org). The integrin expression was
similarly intense in both IPF and control large airway
epithelium. This is consistent with prior studies indicating
strong immunoreactivity to 2 and 1 integrin in the bron-
chial epithelium of normal lung tissue.27,28 Also consis-
tent with prior reports,27 diffuse 2 and 1 immunoreac-
tivity was apparent in cells comprising normal alveolar
septae.
To verify our immunofluorescent results, we performed
IHC. Consistent with our immunofluorescent studies, IHC
analysis of IPF lung tissue demonstrated that fibroblastic
foci displayed a paucity of cells staining for 2 and 1
integrin, whereas relatively intense immunoreactivity for
both 2 and 1 was observed in epithelial cells overlying
the fibrotic reticulum (Figure 2B; see also Supplemental
Figure S3 at http://ajp.amjpathol.org). Diffuse immunore-
activity of 2 and 1 integrin was apparent in cells com-
prising normal alveolar structures in control lung tissue
(Figure 2B).
Low 21 Integrin Expression Is Associated with
a Failure of IPF Fibroblasts to Properly Activate
PP2A Phosphatase Activity in Response to
Interaction with Polymerized Type 1 Collagen
To reconcile our finding that 21 integrin expression is
low in IPF fibroblasts with our expectation that prolifera-
tion signal pathways downstream from integrin are patho-
logically activated in IPF, we reasoned that reductions in
integrin function might lead to diminished function of one
or more key phosphatases that inhibit proliferation sig-
naling. In support of this concept, Heino and col-
leagues24 found that 21 integrin-mediated cell adhe-
sion to collagen led to the induction of activity of the
serine/threonine phosphatase PP2A. This suggested to
us that pathologically low 21 integrin function in IPF
fibroblasts might fail to properly induce PP2A activity
when these cells interact with collagen. Consistent with
this idea, we found that during IPF fibroblast interaction
with polymerized collagen over a 3-day period these cells
226 Xia et al
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ure 3A). In marked contrast, control fibroblasts robustly
induced PP2A activity. At day 3, PP2A activity was 2.98-
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Figure 2. 21 integrin expression is decreased in IPF fibroblastic foci in
vivo. A: Immunofluorescent microscopic analysis was performed on IPF and
control lung specimens (anatomically normal lung) to analyze for 2 and 1
integrin immunoreactivity. In H&E stain of IPF fibroblastic focus (top), the
boxed region corresponds to the area of the immunofluorescent images
(middle) for 2 integrin. Immunofluorescent images demonstrate reduced
immunoreactivity for 2 integrin expression in cells comprising the fibrotic
reticulum, compared with intense 2 integrin immunoreactivity in overlying
epithelial cells. Strong immunoreactivity for -smooth muscle actin (-SMA)
was present in the majority of cells comprising the IPF fibroblastic focus. Control
lung tissue demonstrates diffuse 2 integrin staining of anatomically normal
alveolar structures. Note that 2 integrin immunoreactivity is strong in airway
epithelial cells. Bottom: There is a paucity of 1 integrin immunoreactive cells
within the IPF fibroblastic focus, whereas relatively strong immunoreactivity for
1 integrin is present in epithelial cells overlying the fibroblastic focus. Cells
within the fibroblastic focus are immunoreactive for -smooth muscle actin. A
diffuse pattern of 1 staining was present in cells comprising normal alveolar
septae. The boxed region corresponds to the area of the merged image shown
at higher power. B: IHC microscopic analysis was performed on IPF and ana-
tomically normal control lung specimens to analyze for 2 and 1 immunore-
activity. Representative IHC images demonstrate a paucity of 2 and 1 immu-
noreactivity in cells in IPF fibroblastic foci, but with immunoreactivity in
epithelial cells overlying the fibroblastic focus. Asterisks indicate the features
labeled. AA, alveolar area; BV, blood vessel; EC, epithelial cell; FF, fibroblastic
focus. Original magnification: 400 (A, H&E stain); 400 (A, unmerged immu-
nofluorescence images); 630 (A, merged images); 400 (B).fold higher in control fibroblasts, compared with IPF fi-broblasts. To determine whether the low PP2A activity in
IPF fibroblasts interacting with collagen was due to a lack
of PP2A expression or a failure to activate the phospha-
tase, we examined the expression of the catalytic subunit
of PP2A (PP2Ac) in IPF and control fibroblasts cultured
on polymerized collagen for 3 days. Both IPF and control
fibroblasts expressed PP2Ac. PP2Ac expression was
modestly lower in IPF fibroblasts, compared with control
fibroblasts (Figure 3B). PP2Ac expression, in both IPF
and control fibroblasts, did not appreciably change with
time. These results suggested to us that pathologically
low 21 integrin function fails to appropriately induce
PP2A phosphatase activity during IPF fibroblast interac-
tion with polymerized collagen, whereas normal 21 in-
tegrin function in control fibroblasts facilitates activation
of PP2A.
Inhibition of 21 Integrin and Knockdown of 1
Integrin in Control Fibroblasts Results in an
Inability of These Cells to Activate PP2A in
Response to Interaction with Collagen
To analyze the role of 21 integrin in regulating PP2A
activity in IPF and control fibroblasts, we used integrin
function-blocking antibodies. We used an 2-blocking
antibody that has been shown to specifically interdict
21/collagen-induced signals. Blockage of 2 integrin
inhibited the 21/collagen-mediated induction of PP2A
activity in control fibroblasts (66% decrease in PP2A
IPF                             Control     
1           2           3          1          2          3   (Day)
GAPDH
PP2Ac
IPFControl
PP
2A
 A
ct
iv
ity
 
(%
 C
ha
ng
e)
Day 1
Day 3
0
50
100
150
200
250
300
PP
2A
 A
ct
iv
ity
 
(%
 C
ha
ng
e)
PP
2A
 A
ct
iv
ity
 
(%
 C
ha
ng
e)
A
B
Figure 3. Low 21 integrin expression is associated with a failure of IPF
fibroblasts to properly activate PP2A phosphatase activity in response to
interaction with polymerized type 1 collagen. A: Primary lung fibroblasts
from IPF patients (n  7) and control patients (n  7) were cultured on
polymerized collagen and PP2A phosphatase activity was quantified as a
function of time. B:Western blot analysis for PP2Ac protein expression in IPF
and control fibroblasts cultured on polymerized collagen for 3 days.
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AJP July 2012, Vol. 181, No. 1activity in cells treated with blocking antibody, com-
pared with control; Figure 4A). In contrast, PP2A activ-
ity was low in IPF fibroblasts and did not significantly
change in response to the 2 or 21 integrin-blocking
antibody (Figure 4A).
To confirm that the level of 21 integrin regulates
PP2A activity, we knocked down 1 integrin expression in
control fibroblasts, using shRNA to 1 integrin. The cells
were then plated on polymerized collagen, and PP2A
phosphatase activity was examined as a function of time.
PP2A activity was 3.84-fold higher in control cells treated
with control shRNA, compared with control cells in which
1 integrin had been knocked down (Figure 4B), indicat-
ing that decreasing integrin expression reduces PP2A
activation. Of note, we also overexpressed wild-type 1
integrin in our IPF fibroblasts, as well as the V737N mu-
tant 1 integrin construct (autoclustered 1 integrin).
29
Empty vector was used as a control. Overexpression of
either of the 1 integrin constructs was poorly tolerated
by IPF fibroblasts, however, and we noted a significant
loss of viability (data not shown). Cells treated with empty
vector remained viable.
To further verify that the level of 21 integrin regulates
PP2A activity, we seeded GD25 null fibroblasts, which
lack 21 integrin, and GD25 fibroblasts reconstituted
with 21 integrin on polymerized collagen and examined
PP2A activity. PP2A activity increased more than seven-
fold when GD25-21 cells interacted with polymerized
collagen, compared with GD25 null cells. GD25 null cells,
which are devoid of 21 integrin and adhere poorly to
polymerized collagen, failed to activate PP2A (Figure
Isotope  Control
α2  Blocking Antibody
Control          IPF
)egnah
C
%(
ytivitc
A
A2PP
0
20
40
60
80
100
120
p<0.003
140
)egnah
C
%(
ytivitc
A
A2PP
0
50
100
150
200
250
300
350
400
450
500
PP
2A
 A
ct
iv
ity
 (%
C
ha
ng
e)
Day1
Day3
Control 
shRNA
β1 Integrin
shRNA
PP
2A
 A
ct
iv
ity
 (%
C
ha
ng
e)
Day 1
Day 3
GD25 null  GD25 α2β1
PP
2A
 A
ct
iv
ity
 (%
 C
ha
ng
e)
-200
0
200
400
600
800
1000
PP
2A
 A
ct
iv
ity
 (%
 C
ha
ng
e)0  min.
60 min.
GD25 null     GD25 α2β1
* 
0
20
40
60
80
100
120
140
160
180
200
PP
2A
 A
ct
iv
ity
 (%
 C
ha
ng
e)
PP
2A
 A
ct
iv
ity
 (%
 C
ha
ng
e)
p<0.02
A B
C
p<0.002
Figure 4. Inhibition of 21 integrin and knockdown of 1 integrin in
control fibroblasts results in an inability of these cells to activate PP2A in
response to interaction with collagen. A: IPF and control fibroblasts were
treated with 2 function-blocking antibody or isotype control antibody and
were seeded on collagen matrix. PP2A activity was quantified at 60 minutes.
B: Control fibroblasts were infected with a lentiviral vector containing shRNA
to 1 integrin or control shRNA. The cells were then cultured on polymerized
collagen or tissue culture plates for 3 days, and PP2A phosphatase activity
was quantified. C: GD25 null and GD25-21 fibroblasts were cultured on
polymerized collagen and PP2A activity was quantified. *P  0.01.4C). Taken together, our 21 integrin-blocking antibodystudies, combined with our integrin knockdown studies
using control fibroblasts, support the concept that dimin-
ished 21 integrin expression in IPF fibroblasts results in
a failure of these cells to appropriately activate PP2A in
response to interaction with polymerized type I collagen.
Low PP2A Activity in IPF Fibroblasts Is
Associated with High Levels of Phosphorylated
(Inactive) GSK-3 and Active -Catenin
PP2A phosphatase has been shown to target multiple
substrate serine/threonine kinases for dephosphoryla-
tion.30 Other studies30 have suggested that PP2A can
bind and dephosphorylate Akt. We had previously found
that Akt was aberrantly activated in IPF fibroblasts in
response to their interaction with collagen, whereas the
level of phospho-Akt was low in control fibroblasts.20 We
therefore tested whether PP2A could interact with Akt in
control fibroblasts during their interaction with polymer-
ized collagen. Surprisingly, we were unable to detect a
binding association of PP2A with Akt in our control fibro-
blasts (data not shown). We also analyzed the effect of
the PP2A inhibitor okadaic acid on the level of Akt phos-
phorylation in control fibroblasts cultured on polymerized
collagen. We did not detect a significant change in the
level of phospho-Akt in control fibroblasts treated with the
PP2A inhibitor (data not shown). Together, these data
indicate that Akt is not a major substrate for PP2A in our
primary control fibroblasts during their interaction with
polymerized collagen.
The -catenin pathway has been shown to be acti-
vated in IPF.22,23 GSK-3 has also been shown to be a
substrate for PP2A; when dephosphorylated, GSK-3 is
active and inhibits -catenin.30 Next, therefore, we ana-
lyzed the level of phosphorylated (inactive) GSK-3 in IPF
and control fibroblasts cultured on polymerized collagen
as a function of time. Consistent with a failure of IPF
fibroblasts to activate PP2A in response to interaction
with collagen, we found that the level of phosphorylated
(inactive) GSK was elevated in IPF fibroblasts, compared
with control fibroblasts; In control fibroblasts, however, the
level of GSK-3 correlated inversely with PP2A activity. As
PP2A activity increased during control fibroblast interaction
with collagen, the level of inactive GSK-3 decreased (Fig-
ure 5A). This suggested that inappropriately low PP2A
phosphatase activity in IPF fibroblasts results in elevated
levels of phosphorylated (inactive) GSK-3.
When active, GSK-3 phosphorylates -catenin,
thereby targeting it for proteasomal degradation.31 Be-
cause we have found that the level of inactive GSK-3 is
high in IPF fibroblasts cultured on polymerized collagen,
we expected that active -catenin levels would also be
high. Consistent with this idea, we found that the level of
active -catenin was elevated in IPF fibroblasts cultured
on polymerized collagen, compared with control fibro-
blasts (Figure 5A). Furthermore, at day 3 of control fibro-
blast interaction with polymerized collagen, a time when
PP2A activity is very high (Figure 3A), the levels of both
inactive GSK-3 and active -catenin were significantly de-
pressed (Figure 5A). These data support the idea that de-
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fibroblasts, which then leads to inactivation of GSK-3 and
consequently elevated levels of active -catenin.
We also examined the location of active -catenin in
IPF and control fibroblasts cultured on polymerized col-
lagen by immunofluorescent analysis. Consistent with its
function as a transcription factor, active -catenin was
present in the nuclei of IPF fibroblasts cultured on colla-
gen. In contrast, little or no nuclear -catenin could be
detected in control fibroblasts (Figure 5B). These data
are consistent with reports indicating high levels of active
-catenin in IPF.22,23
Inhibition of 21 Integrin and Knockdown of 1
Integrin Increases the Level of Phosphorylated
GSK-3 and Active -Catenin in Control
Fibroblasts
Expression of 21 integrin and activity levels of PP2A are
low in IPF fibroblasts, and the level of inactive or phos-
phorylated GSK-3 is high. We found the opposite in
control fibroblasts, in which 21 integrin expression and
PP2A activity levels are relatively high but the level of
IPF 
Active β-Catenin
Control                   IPF 
1 2          3         1       2        3        (Day) 
GAPDH
p-GSK3 β Ser9
Active β-Catenin
A
B Control
Active β-Catenin
Figure 5. Low PP2A activity in IPF fibroblasts is associated with high levels
of phosphorylated (inactive) GSK-3 and active -catenin. A: Western blot
analysis of phospho-GSK-3 and active -catenin in IPF and control fibro-
blasts cultured on polymerized collagen matrix for up to 3 days. GAPDH was
the loading control. B: IPF and control fibroblasts were cultured on cover-
slips coated with polymerized collagen and the location of active -catenin
(red) was examined by immunofluorescent microscopic analysis. DAPI
(blue) was used as a nuclear counterstain. Original magnification, 400.phosphorylated GSK-3 is low. This suggested a linkbetween integrin expression/function and phospho-
GSK-3 levels. To analyze the role of 21 integrin in
regulating GSK-3 and -catenin activity in IPF and con-
trol fibroblasts, we used the 2 integrin function-blocking
antibody. Inhibition of 21 function by the blocking an-
tibody augmented the expression of phosphorylated (in-
active) GSK-3 expression and increased the level of
active -catenin in control fibroblasts during interaction
with polymerized collagen (Figure 6A). Inhibition of 21
function by the blocking antibody did not appreciably
alter the level of either inactive GSK-3 expression or
active -catenin in IPF fibroblasts, presumably because
21 integrin expression is very low in IPF fibroblasts,
resulting in a failure of these cells to appropriately acti-
vate PP2A. To verify that integrin expression regulates the
level of phosphorylated GSK-3 in our primary fibroblasts,
we next examined the effect of knockdown of 1 integrin on
the level of phosphorylated GSK-3 and active -catenin in
control fibroblasts. Knockdown decreased the level of total
1 integrin (Figure 6B). In response to knockdown of 1
integrin, the level of phospho-GSK-3 was increased,
compared with control fibroblasts treated with control
shRNA (Figure 6B). Consistent with the result that knock-
down of 1 integrin facilitates inactivation of GSK-3,
knockdown also resulted in augmentation of the level of
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- +       - +       α2 Blocking Antibody
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60      60 60 60 (min)
Active  β-Catenin
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C
Figure 6. Inhibition of 21 integrin and knockdown of 1 integrin in-
creases the level of phosphorylated GSK-3 and active -catenin in control
fibroblasts. A: IPF and control fibroblasts were plated on polymerized colla-
gen (PC) in the presence of 2 integrin-blocking antibody or isotype control
antibody, and the levels of phosphorylated GSK-3 and active -catenin
were examined by Western blot analysis at 60 minutes. B: Control fibroblasts
were infected with a lentiviral vector containing shRNA to 1 integrin or
control shRNA. The cells were cultured on polymerized collagen, and the
levels of total and active 1 integrin (left) and phosphorylated GSK-3 and
active -catenin (right) were examined by Western blot analysis at day 3.
GAPDH was the loading control. C: GD25 null and GD25-21 fibroblasts
were cultured on polymerized collagen and the levels of phosphorylated
GSK-3 and active -catenin were examined by Western blot analysis.
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decreasing 1 integrin function results in the phosphory-
lation and inactivation of GSK-3, thereby augmenting
-catenin activity.
To confirm that the level of 21 regulates the levels of
phospho-GSK-3 and active -catenin in response to
fibroblast interaction with collagen, we seeded GD25 null
cells lacking 21 integrin and GD25 cells reconstituted
with 21 integrin on polymerized collagen and examined
phospho-GSK-3 and active -catenin levels. We found
that the levels of phospho-GSK-3 (inactive) and active
-catenin were high in GD25 cells lacking 21, com-
pared with GD25 cells reconstituted with 21 integrin
(Figure 6C). Taken together, these findings strongly sup-
port the idea that, when IPF fibroblasts interact with col-
lagen, low 21 integrin expression fails to activate PP2A,
leading to higher levels of inactive or phosphorylated
GSK-3 and high levels of active -catenin.
Knockdown of PP2Ac in Control Fibroblasts
Increases Phospho-GSK-3 Levels
To examine the effect of PP2A activity on GSK-3 phos-
phorylation, we inhibited PP2A activity in control fibro-
blasts cultured on collagen using the PP2A inhibitor oka-
daic acid. Inhibition of PP2A activity by okadaic acid
dramatically increased the level of phosphorylated
GSK-3 in control fibroblasts and enhanced the level of
active -catenin (Figure 7A). To verify this result, we
knocked down the catalytic subunit of PP2A using shRNA
to the PP2Ac subunit and examined the effect on the
level of phospho-GSK-3. Knockdown of PP2Ac resulted
in increased levels of phosphorylated GSK-3 in control
fibroblasts (Figure 7B). Taken together, these results
strongly suggest that low 21 integrin function reduces
PP2A activity, which results in higher levels of phosphor-
ylated (inactive) GSK-3. We also overexpressed the cat-
alytic subunit of PP2A in our IPF fibroblasts, to examine
the effect on GSK-3. Notably, similar to overexpression
of wild-type 1 integrin or autoclustered 1 integrin, over-
expression of PP2Ac in our IPF fibroblasts resulted in a
substantial loss of viability, suggesting that up-regulation
of the 21 integrin/PP2A pathway is not tolerated in IPF
fibroblasts. IPF fibroblasts treated with empty vector be-
haved similarly to untreated cells.
Knockdown of 1 Integrin and PP2Ac in Control
Fibroblasts, as Well as Inhibition of GSK-3,
Enhances Their Proliferation on Polymerized
Collagen
Control fibroblast proliferation is suppressed by polymer-
ized collagen.6–8 We have shown that knockdown of 1
integrin in control fibroblasts decreases PP2A activity
while increasing the level of inactive GSK-3 and the
level of active -catenin. We therefore analyzed the effect
of knockdown of 1 integrin on control fibroblast prolifer-
ation on polymerized collagen. Knockdown of 1 integrin
induced a modest 26% increase in the proliferation of
control fibroblasts on polymerized collagen at day 3,compared with cells treated with control shRNA (Figure
8A). This may be due to alterations in cell adhesion due
to the reduction in 1 integrin levels. Because we have
found that PP2A activity is robustly induced when control
fibroblasts interact with polymerized collagen and that
this results in increased levels of active GSK-3, we next
knocked down PP2Ac by shRNA and examined the effect
on control fibroblast proliferation. The proliferation of con-
trol fibroblasts in which PP2Ac was knocked down was
markedly increased, by 51%, compared with cells
treated with control shRNA (Figure 8B). These data indi-
cate that a reduction in 1 integrin or PP2A levels aug-
ments control fibroblast proliferation on polymerized col-
lagen, replicating the behavior of IPF fibroblasts on
polymerized collagen. Note, however, that because over-
expression of our 1 integrin constructs in IPF fibroblasts
was not tolerated, we were unable to examine the effect
of overexpression of 1 integrin on IPF fibroblast prolifer-
ation on collagen.
Our data indicate that, when cultured on collagen,
control fibroblasts display higher amounts of active
GSK-3 and their proliferation is suppressed to a greater
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shRNA shRNA
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Figure 7. Knockdown of PP2Ac in control fibroblasts increases phospho-
GSK-3 levels. A: Control fibroblasts were pretreated with 20 mol okadaic
acid (OA) or control vehicle and then were cultured on polymerized collagen
for up to 3 days. The levels of phosphorylated GSK-3 and active -catenin
were examined by Western blot analysis. B: Control fibroblasts were infected
with a lentiviral vector containing shRNA to the catalytic  subunit of PP2A
(PP2Ac) or control shRNA. The cells were then cultured on polymerized
collagen and the levels of phosphorylated GSK-3 and active -catenin were
examined by Western blot analysis.extent, compared with IPF fibroblasts, suggesting that
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proliferation. We therefore examined the effect of inhibi-
tion of GSK-3 by LiCl on control fibroblast proliferation
on polymerized collagen. Inhibition of GSK-3 by LiCl
increased control fibroblast proliferation by approxi-
mately threefold, compared with cells treated with vehicle
control (Figure 8C). These data, combined with data from
our knockdown studies of 1 integrin and PP2Ac, support
the idea that, in control fibroblasts, high levels of 21
integrin activate PP2A and increase the level of active
GSK-3. Active GSK-3 reduces active -catenin,
thereby suppressing proliferation.
Knockdown of -Catenin in IPF Fibroblasts
Decreases Their Ability to Proliferate on
Polymerized Collagen
Our studies suggest that pathologically low 21 integrin
results in activation of the -catenin proliferation signal
pathway and that aberrantly high levels of -catenin fa-
cilitate the ability of IPF fibroblasts to elude the prolifera-
tion-suppressive properties of polymerized collagen. To
investigate this possibility further, we knocked down
-catenin in IPF fibroblasts using -catenin shRNA and
examined their proliferative ability on polymerized colla-
gen. The level of -catenin in IPF fibroblasts treated with
-catenin shRNA was reduced, compared with cells
treated with control shRNA (Figure 9A). Importantly,
knockdown of -catenin reduced the proliferative capac-
ity of IPF fibroblasts cultured on polymerized collagen by
46%, compared with control shRNA (Figure 9B). These
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Figure 8. Knockdown of 1 integrin or PP2Ac and inhibition of GSK-3 in
control fibroblasts enhances their proliferation on polymerized collagen. A:
Control fibroblasts were infected with a lentiviral vector containing shRNA to
1 integrin or control shRNA. The cells were then cultured on polymerized
collagen for 3 days, at which time cell numbers were quantified. B: Control
fibroblasts were infected with a lentiviral vector containing shRNA to PP2Ac
or control shRNA and cultured on polymerized collagen. Cell numbers were
quantified at day 3. C: Control fibroblasts were cultured on polymerized
collagen matrix in DMEM with 10% fetal calf serum containing 20 mmol/L
LiCl or vehicle control (sterile water). Cell numbers were quantified at day 3.data support the hypothesis that activation of -cateninby deficient 21 integrin function enhances IPF fibro-
blast proliferation on collagen.
Discussion
The pathogenesis of IPF remains incompletely under-
stood. An ongoing question in IPF concerns the unrelent-
ing nature of the fibroproliferative response. A current
paradigm for IPF suggests that injury to the epithelium
generates a pathological fibroproliferative response.32–34
During normal tissue repair after injury, fibroproliferation
is induced but then rapidly abates. In IPF, however, the
fibroproliferative process never appears to abate. Prog-
ress in our understanding of this lethal disease and the
development of effective medical strategies to combat it
depends on an improved understanding of this relentless
fibroproliferative process.
In an attempt to understand this progressive fibrotic
disease, we have focused our investigations on the fi-
broproliferative process itself and on its key cellular con-
stituent, the myofibroblast. Several studies indicate that
the IPF fibroblast displays a distinct pathological pheno-
type, one that shares several features in common with the
cancer-associated fibroblast phenotype.35–38 We have
found that the IPF fibroblast, similar to cancer-associated
fibroblasts, displays low caveolin-1 expression and low
PTEN function, resulting in aberrant activation of the
PI3K/Akt/S6K1 signal pathway.20,21
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Figure 9. Knockdown of -catenin in IPF fibroblasts decreases their ability
to proliferate on polymerized collagen. IPF fibroblasts were infected with a
lentiviral vector containing shRNA to -catenin or control shRNA and cul-
tured on polymerized collagen matrix in DMEM with 10% fetal calf serum for
3 days. A: Western blot analysis of -catenin levels in IPF fibroblasts treated
with -catenin shRNA or control shRNA. B: Cell numbers were quantified at
day 3.
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fibroblast has acquired a distinct phenotype character-
ized by its ability to proliferate in a type I collagen prolif-
eration-suppressive environment. We have discovered
that 21 integrin expression is abnormally reduced in
IPF fibroblasts and that this altered integrin function con-
fers these cells with their pathological proliferative re-
sponse. Previous work by Heino and colleagues24 estab-
lished that, during cell adhesion to polymerized type I
collagen, 21 integrin (which is a major collagen recep-
tor) induces activation of the PP2A phosphatase. Here,
we have demonstrated that low 21 integrin expression
is a characteristic of the IPF fibroblast phenotype. Our
data support the concept that the pathological decrease
in 21 integrin expression in IPF fibroblasts results in a
failure of the integrin to properly activate PP2A phospha-
tase. In addition, we show that, during IPF fibroblast
interaction with collagen, PP2A activity remains inappro-
priately low. In contrast, when control fibroblasts interact
with collagen, PP2A is induced, with levels rising more
than twofold. Importantly, knockdown of 1 integrin or
inhibition of 21 by blocking antibody in control fibro-
blasts impairs the ability of these cells to activate PP2A
when interacting with polymerized collagen, mimicking
IPF fibroblast behavior. Furthermore, we demonstrate
that GD25 null cells, which are devoid of 21, are unable
to activate PP2A, whereas GD25 cells reconstituted with
21 appropriately activate PP2A in response to interac-
tion with polymerized collagen. Note that, similar to IPF
fibroblasts, GD25 cells do not activate PP2A, because
they are devoid of 21 integrin. Unlike IPF fibroblasts,
however, GD25 cells display decreased proliferation on
polymerized collagen, despite reduced PP2A activity,
because their complete lack of 21 results in a mark-
edly impaired ability to attach to polymerized collagen.
In contrast, despite reduced 21, IPF fibroblasts read-
ily attach to polymerized collagen and, because of
activation of the -catenin pathway, they demonstrate
the ability to elude the proliferation-suppressive effects
of polymerized collagen.
PP2A is a serine/threonine phosphatase that has been
shown to target multiple serine/threonine kinases includ-
ing Akt and GSK-3.30 Our data indicate that a major
PP2A target in our IPF and control fibroblasts is GSK-3.
Previous studies have identified Akt as a PP2A sub-
strate.30 We have previously shown that Akt is abnormally
activated in IPF, and the present work indicates that IPF
fibroblasts display low PP2A activity.20 Thus, Akt could
be elevated because of a failure of the integrin to activate
PP2A. However, our present work suggest that this is not
the case. We have been unable to detect direct interac-
tion of PP2A with Akt in control fibroblasts, and treatment
of control fibroblasts with the PP2A inhibitor okadaic acid
did not augment the level of phospho-Akt. Furthermore,
our prior studies indicate that inappropriately low PTEN
function is responsible for activation of the PI3K/Akt sig-
nal pathway in IPF fibroblasts.20 However the strongest
indications that GSK-3 is a major PP2A target come
from our present results: i) the consequence of inappro-
priately low PP2A phosphatase activity in our IPF fibro-
blasts was an abnormally high level of phosphorylated(inactive) GSK-3 resulting in aberrantly high levels of
-catenin and pathological proliferation (Figure 10);
ii) inhibition of PP2A in control fibroblasts increased the
levels of phosphorylated GSK-3 and -catenin; and iii)
knockdown of integrin in our control fibroblasts also in-
creased the level of both inactive GSK-3 and active
-catenin.
Our present findings indicate that abnormal integrin
function leads to a pathological pattern of integrin signal-
ing, resulting in aberrant activation of the -catenin path-
way. Furthermore, we have found that IPF fibroblasts
have eluded the proliferation-suppressive effects of po-
lymerized collagen. We therefore sought to examine the
consequence of the altered integrin/PP2A axis on prolif-
eration. Because 21 expression and PP2A activity are
reduced in IPF, compared with control fibroblasts, we
chose a knockdown approach, to more closely model this
difference in integrin expression and PP2A activity be-
tween IPF and control fibroblasts and to assess the role of
the 21/PP2A axis in regulating proliferation. We
avoided complete knockdown of 1 integrin, so that the
cells could still effectively adhere to collagen. We also
specifically avoided the use of integrin-blocking antibod-
ies in our attempt to model the effect of reduced integrin
expression on proliferation, because blocking antibodies
disrupt adhesion and as a consequence disrupt prolifer-
ation. We found that reducing 1 integrin expression or
PP2A levels resulted in inactivation of GSK-3 and in-
creased levels of active -catenin, as well as augmented
ability of control fibroblasts to proliferate on polymerized
collagen, thereby mimicking IPF fibroblast behavior. Im-
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Figure 10. Schematic of a working model for integrin regulation of IPF
fibroblast proliferation. Left: In response to control fibroblast interaction with
fibrillar collagen, high 21 integrin expression activates PP2A, promoting
dephosphorylation and activation of its target substrate GSK-3. This causes
inactivation of -catenin and suppression of proliferation. Right: During IPF
fibroblast interaction with fibrillar collagen, low 21 integrin expression fails
to appropriately activate PP2A. This causes an accumulation of phosphory-
lated (inactive) GSK-3 promoting activation of -catenin and pathological
proliferation. Note that data from additional studies32,33 indicate that certain
growth factors, such as TGF, also activate proliferation signaling pathways
in IPF fibroblasts Thus, available data indicate that a collaboration between
matrix and growth factors controls the abnormal proliferation of IPF fibro-
blasts.portantly, we show here that the knockdown of -catenin in
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lymerized collagen. We suggest that this aberrant integrin
function will be fundamental to understanding the relentless
nature of this prototypical fibroproliferative disease.
A critical remaining issue for future studies will be to
delineate the molecular mechanism underlying the
pathologically low 21 integrin expression and activa-
tion in IPF fibroblasts. Another question to be addressed
is whether abnormally low 21 integrin function results in
the compensatory increase of other integrin receptor
functions. Whether there is compensatory alteration in other
matrix receptors that contribute to pathological proliferation
signaling remains unclear at this time. An additional ques-
tion surrounds the origin of the pathological IPF fibroblast.
Experimental evidence suggests that IPF fibroblasts may
arise from at least three possible sources: resident fibro-
blasts, epithelial cells that have undergone epithelial to
mesenchymal transition, and/or circulating fibrocytes re-
cruited to the lung from the bone marrow.39–45 Additional
studies are needed to determine the origin of IPF fibroblasts
that display this pathological integrin function.
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